Patents Examined by Jessica H. Roark
  • Anti-TIGIT antigen-binding proteins and methods of use thereof
    Patent number: 10507244
    Abstract: Provided herein are antigen-binding proteins (ABPs) that selectively bind to TIGIT and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: December 17, 2019
    Assignee: Potenza Therapeutics, Inc.
    Inventors: Daniel Hicklin, William Winston, Cynthia Seidel-Dugan, Nels P. Nielson
  • Method for detecting lung squamous cell carcinoma
    Patent number: 10502743
    Abstract: The present invention provides a method by which lung squamous cell carcinoma can be detected in a simple and prompt manner with high detection performance; and the like. The method according to the present invention detects lung squamous cell carcinoma by an assessment including the steps of: (1) performing measurement of the desmoglein 3 content in a blood sample collected from a subject; and (2) comparing the desmoglein 3 content determined by the measurement with the desmoglein 3 content in a blood sample collected from a healthy individual so as to estimate the presence of lung squamous cell carcinoma in the subject when the desmoglein 3 content is higher in the blood sample collected from the subject.
    Type: Grant
    Filed: October 9, 2012
    Date of Patent: December 10, 2019
    Assignees: KONICA MINOLTA, INC., CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Takeshi Isoda, Nao Noro, Tomonori Kaneko
  • Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
    Patent number: 10501550
    Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: December 10, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Changyu Wang, Nils Lonberg, Alan J. Korman, Mark J. Selby, Mohan Srinivasan, Karla A. Henning, Michelle Minhua Han, Guodong Chen, Richard Huang, Indrani Chakraborty, Haichun Huang, Susan Wong, Huiming Li
  • Methods for treating cancer
    Patent number: 10501537
    Abstract: The present invention provides methods of treating cancer, particularly cancers that had developed resistance to PD-1 and PDL-1 blockade. Also included are methods of identifying therapeutic targets for the treatment of cancer.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: December 10, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventor: Kwok-Kin Wong
  • Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma
    Patent number: 10494433
    Abstract: Provided are methods for clinical treatment of multiple myeloma using an anti-KIR antibody in combination with an anti-CS 1 antibody.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: December 3, 2019
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, Innate Pharma
    Inventors: Pascale Andre, Mathieu Blery, Cecile Bonnafous, Ashok K. Gupta, Luisa M. Salter-Cid, Michael Darron Robbins
  • Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
    Patent number: 10479839
    Abstract: This invention provides a method that allows selection of antibodies against cells (e.g., tumor cells) in situ using laser capture microdissection. By restricting antibody selection to binders of internalizing epitopes, a panel of phage antibodies was generated that targets clinically represented prostate cancer antigens.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: November 19, 2019
    Assignee: The Regents of the University of California
    Inventors: Bin Liu, James D. Marks
  • BCR-complex-specific antibodies and methods of using same
    Patent number: 10479831
    Abstract: This invention relates to chimeric and humanized antibodies that specifically bind the BCR complex, and particularly chimeric and humanized antibodies to the BCR complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: November 19, 2019
    Assignee: MacroGenics, Inc
    Inventors: Leslie S. Johnson, Ling Huang
  • Disulfide stabilized DVD-Ig molecules
    Patent number: 10472426
    Abstract: The present disclosure provides a binding protein comprising: a polypeptide heavy chain comprising: VH1-(X1)n-VH2—CH (X2)y wherein VH1 is a first variable domain, VH2 is a second variable domain, CH is a constant domain, X1 represents an amino acid or peptide, X2 represents an Fc region, n is 0 or 1 and y is independently 1 or 2, and a polypeptide light chain comprising: VL1-(X1)n-VL2-C wherein VL1 is a first variable domain, VL2 is a second variable domain, C is a constant domain, X1 represents an amino acid or peptide and n is 0 or 1, wherein the heavy chain and light chain are aligned such that VH1 and VL1 form a first binding domain, and VH2 and VL2 form a second binding domain and wherein: there is a disulfide bond between VH1 and VL1, and/or there is a disulfide bond between VH2 and VL2, and use thereof in treatment.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: November 12, 2019
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Sam Philip Heywood, David Paul Humphreys
  • Multivalent antibodies
    Patent number: 10421816
    Abstract: The present invention provides a multivalent antibody or a heavy/light chain component thereof comprising: a heavy chain comprising a constant region fragment, said constant region fragment located between two variable domains which are not a cognate pair, the heavy chain further comprising an Fc region with at least one domain selected from CH2, CH3 and combinations thereof, with the proviso that the heavy chain contains no more than one CH1 domain and only contains two variable domains, and a light chain comprising a constant region fragment located between two variable domains which are not a cognate pair, wherein said heavy and light chains are aligned to provide a first binding site formed by a first cognate pair of variable domains and a second binding site formed by a second cognate pair of variable domains.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: September 24, 2019
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Ralph Adams, Emma Dave, David Paul Humphreys
  • Human monoclonal antibodies against AXL
    Patent number: 10398774
    Abstract: The present disclosure provides human monoclonal antibodies and antibody-drug conjugates against AXL and their use for the treatment of cancer.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: September 3, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE MONTPELLIER, INSTITUT REGIONAL DU CANCER DE MONTPELLIER
    Inventors: Bruno Robert, Christel Larbouret, Pierre Martineau, Marie-Alix Poul
  • Subcutaneous formulations of anti-CD38 antibodies and their uses
    Patent number: 10385135
    Abstract: The present invention relates to subcutaneous formulations of anti-CD38 antibodies and their uses.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: August 20, 2019
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Richard Jansson, Vineet Kumar
  • Engineered antibody constant domain molecules
    Patent number: 10358481
    Abstract: Described herein are engineered antibody constant domain molecules, such as CH2 or CH3 domain molecules, comprising at least one mutation, or comprising at least one complementarity determining region (CDR), or a functional fragment thereof, engrafted in a loop region of the CH2 domain. The CH2 domain molecules described herein are small, stable, soluble, exhibit little to no toxicity and are capable of binding antigen.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: July 23, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: Dimiter S. Dimitrov
  • Compositions comprising anti-CD38 antibodies and lenalidomide
    Patent number: 10342869
    Abstract: Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and lenalidomide compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: July 9, 2019
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SANOFI
    Inventors: Byron C. Hann, Blake Tomkinson, Thomas G. Martin, III, Blake T. Aftab
  • Antibody and antibody composition production method
    Patent number: 10344099
    Abstract: [Problem] To provide: an antibody comprising at least two kinds of Fab, and in particular having restricted light chain-heavy chain combinations; a corresponding antibody composition; and production methods for same. [Solution] The present invention provides production methods for (1) an antibody or (2) an antibody composition, the methods using non-natural disulfide bonds.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: July 9, 2019
    Assignee: ZENYAKU KOGYO KABUSHIKIKAISHA
    Inventors: Jumpei Enami, Tetsuo Sasaki, Hirokazu Suzuki
  • PD1 and/or LAG3 binders
    Patent number: 10323090
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: June 18, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, David Vlerick, Robert A. Kastelein
  • Immunological reagents
    Patent number: 10294299
    Abstract: This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch (“P2”) on PD-1 that is linked with a previously unidentified functional activity of PD-1 that is distinct from the interaction site involved with either the PD-L1 or PD-L2 ligands. Furthermore, we demonstrate that antibodies that interact with this region of PD-1 are able to act as antagonists of PD-1 and that this antagonism is further enhanced with the addition of antibodies that act through the blockade of the PD-1/PD-L1/L2 interaction.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: May 21, 2019
    Assignee: MabQuest SA
    Inventors: Giuseppe Pantaleo, Craig Fenwick
  • Methods of making chimeric antigen receptor-expressing cells
    Patent number: 10273300
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: April 30, 2019
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, Jr., Zoe Zheng
  • CD27L antigen binding proteins
    Patent number: 10266604
    Abstract: The present invention relates to CD27L antigen binding proteins, such an antibodies, polynucleotides encoding said CD27l antigen binding proteins, antibody drug conjugate compositions, and methods for diagnosing and treating diseases associated with CD27L expression.
    Type: Grant
    Filed: January 10, 2017
    Date of Patent: April 23, 2019
    Assignee: AMGEN INC.
    Inventors: John M. Delaney, William Christian Fanslow, III, Chadwick Terence King
  • Insertable variable fragments of antibodies and modified ?1-?2 domains of NKG2D ligands, and non-natural NKG2D ligands that bind non-natural NKG2D receptors
    Patent number: 10259858
    Abstract: This application relates generally to the production of polypeptides having specific antigen-binding properties of Fv domains, for example, insertable variable fragments of antibodies, and modified ?1-?2 domains of NKG2D ligands.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: April 16, 2019
    Assignee: XYPHOS BIOSCIENCES INC.
    Inventors: Kyle Landgraf, Daniel P. Steiger, Tarah Baron, Dana Gebhart
  • Therapeutic CD47 antibodies
    Patent number: 10259873
    Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of, CD47, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents that are toxic to susceptible cancer cells, promoting their phagocytic uptake and clearance, or directly killing such cells.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: April 16, 2019
    Assignee: Arch Oncology, Inc.
    Inventors: William A. Frazier, Pamela T. Manning, Gerhard Frey, Hwai Wen Chang